Search

Your search keyword '"Topol, Eric J"' showing total 352 results
Start Over Author "Topol, Eric J" Publisher elsevier b.v.
352 results on '"Topol, Eric J"'

1. Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management.

Author

Muse, Evan D. and Topol, Eric J.

Abstract

The rise of artificial intelligence (AI) has revolutionized various scientific fields, particularly in medicine, where it has enabled the modeling of complex relationships from massive datasets. Initially, AI algorithms focused on improved interpretation of diagnostic studies such as chest X-rays and electrocardiograms in addition to predicting patient outcomes and future disease onset. However, AI has evolved with the introduction of transformer models, allowing analysis of the diverse, multimodal data sources existing in medicine today. Multimodal AI holds great promise in more accurate disease risk assessment and stratification as well as optimizing the key driving factors in cardiometabolic disease: blood pressure, sleep, stress, glucose control, weight, nutrition, and physical activity. In this article we outline the current state of medical AI in cardiometabolic disease, highlighting the potential of multimodal AI to augment personalized prevention and treatment strategies in cardiometabolic disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study

Author

Mak, Koon-Hou, Bhatt, Deepak L., Shao, Mingyuan, Hankey, Graeme J., Easton, J. Donald, Fox, Keith A.A., and Topol, Eric J.

Subjects
Blood platelets -- Aggregation, Blood platelets -- Complications and side effects, Medical colleges, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2008.08.031 Byline: Koon-Hou Mak (a), Deepak L. Bhatt (b), Mingyuan Shao (c), Graeme J. Hankey (d), J. Donald Easton (e), Keith A.A. Fox (f), Eric J. Topol (g) Abstract: Atherothrombosis is a common condition affecting individuals worldwide. Its impact on different ethnic groups receiving evidence-based therapy is unclear. We aimed to determine if ethnicity is an independent predictor for cardiovascular events and bleeding complications in a contemporary clinical trial on antiplatelet therapy. Author Affiliation: (a) Gleneagles Medical Centre, Singapore, Singapore (b) VA Boston Healthcare System and Brigham and Women's Hospital, Boston, MA (c) Cleveland Clinic, Cleveland, OH (d) Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (e) Department of Neurology, Rhode Island Hospital and Brown University, Providence, RI (f) University and Royal Infirmary of Edinburgh, Edinburgh, UK (g) Scripps Translational Research Institute, La Jolla, CA Article History: Received 13 April 2008; Accepted 20 August 2008 Article Note: (footnote) The CHARISMA trial is registered with ClinicalTrials.gov, NCT00050817.

Published
2009

3. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

Author

Aronow, Herbert D., Steinhubl, Steven R., Brennan, Danielle M., Berger, Peter B., and Topol, Eric J.

Subjects
Blood platelets -- Aggregation, Transluminal angioplasty, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2008.09.011 Byline: Herbert D. Aronow (a), Steven R. Steinhubl (b), Danielle M. Brennan (c), Peter B. Berger (d), Eric J. Topol (e) Abstract: The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention (PCI) is unknown. Incremental reductions in the risk of major adverse cardiovascular events may be partially offset by an increased incidence of bleeding in the months after a PCI. Author Affiliation: (a) Clinical Scholars Program, Michigan Heart and Vascular Institute at St. Joseph Mercy Hospital, Ann Arbor, MI (b) Division of Cardiology, University of Kentucky, Lexington, KY (c) Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH (d) Geisinger Clinic, Danville, PA (e) Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA Article History: Received 29 March 2008; Accepted 14 September 2008 Article Note: (footnote) The CREDO trial was funded by Bristol-Myers Squibb (New York, NY)/Sanofi-Synthelabo (Paris, France) partnership. The study sponsors played no role in the design of this substudy, nor in the collection, analysis, or interpretation of these data., Dr. Aronow is on the Speakers' Bureau for and has received grant funding from Bristol-Myers Squibb-Sanofi. Ms. Brennan has no conflicts of interest to disclose. Drs Topol and Steinhubl received research grants from Sanofi-Aventis and Bristol-Myers Squibb to conduct the trial; Dr. Steinhubl served as a consultant to this company in the clinical development of clopidogrel. Dr Steinhubl is currently employed by the Medicines Company (Parsippany, NJ). Dr Berger has received honoraria for speaking at Bristol-Myers Squibb-Sanofi-sponsored symposia.

Published
2009

4. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy

Author

Tang, W.H. Wilson, Steinhubl, Steven R., Van Lente, Frederick, Brennan, Danielle, McErlean, Ellen, Maroo, Anjli, Francis, Gary S., and Topol, Eric J.

Subjects
Transluminal angioplasty -- Patient outcomes, Transluminal angioplasty -- Research, Cardiac patients -- Prognosis, Cardiac patients -- Research, Natriuretic peptides -- Analysis, Cardiac output -- Analysis, Health
Published
2007

5. The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience

Author

Goodman, Shaun G., Fu, Yuling, Langer, Anatoly, Barr, Aiala, Tan, Mary, Wagner, Galen S., Barbagelata, Alejandro, Sgarbossa, Elena B., Birnbaum, Yochai, Granger, Christopher B., Califf, Robert M., Van de Werf, Frans, Topol, Eric J., and Armstrong, Paul W.

Subjects
Electrocardiogram -- Analysis, Electrocardiography -- Analysis, Coronary heart disease -- Patient outcomes, Coronary heart disease -- Research, Cardiac patients -- Prognosis, Hospitals -- Admission and discharge, Hospitals -- Research, Health
Published
2006

6. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)u2 trial

Author

Exaire, J. Emilio, Butman, Samuel M., Ebrahimi, Ramin, Kleiman, Neal S., Harrington, Robert A., Schweiger, Marc J., Bittl, John A., Wolski, Kathy, Topol, Eric J., and Lincoff, A. Michael

Subjects
Glycoproteins -- Physiological aspects, Glycoproteins -- Research, Heparin -- Physiological aspects, Heparin -- Research, Clinical trials -- Evaluation, Cardiac patients -- Drug therapy, Cardiac patients -- Physiological aspects, Cardiac patients -- Research, Health
Published
2006

7. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial

Author

Rajagopal, Vivek, Lincoff, A. Michael, Cohen, David J., Gurm, Hitinder S., Hu, Tingfei, Desmet, Walter J., Kleiman, Neal S., Bittl, John A., Feit, Frederick, and Topol, Eric J.

Subjects
Cardiac patients -- Care and treatment, Cardiac patients -- Research, Clinical trials -- Evaluation, Heart attack -- Care and treatment, Heart attack -- Research, Heparin -- Physiological aspects, Health
Published
2006

9. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials

Author

Galla, John M., Mahaffey, Kenneth W., Sapp, Shelly K., Alexander, John H., Roe, Matthew T., Ohman, E. Magnus, Granger, Christopher B., Armstrong, Paul W., Harrington, Robert A., White, Harvey D., Simoons, Maarten L., Newby, L. Kristin, Califf, Robert M., and Topol, Eric J.

Subjects
Creatine kinase -- Research, Coronary heart disease -- Diagnosis, Coronary heart disease -- Patient outcomes, Cardiac patients -- Prognosis, Clinical trials -- Reports, Health
Published
2006

10. Creation of a large-scale genetic data bank for cardiovascular association studies

Author

Agah, Ramtin, Ellis, Stephen, Chase, Sue, Henderson, Mark, Mlady, Lisa, Murugesan, Gurunathan, Tubbs, Raymond, Marchant, Kandice, Warshawsky, Ilka, Rouse, Colleen, Hughes, Kathy, Welch, Patricia, and Topol, Eric J.

Subjects
Database administration -- Research, Genetic research -- Management, Cardiovascular research -- Management, Company business management, Health
Published
2005

11. The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial

Author

Brener, Sorin J., Lincoff, A. Michael, Bates, Eric R., Jia, Gang, Armstrong, Paul W., Guetta, Victor, Hochman, Judith S., Savonitto, Stefano, Wilcox, Robert G., White, Harvey D., and Topol, Eric J.

Subjects
Heart attack -- Care and treatment, Heart attack -- Risk factors, Reperfusion (Physiology) -- Research, Thrombolytic therapy -- Patient outcomes, Health
Published
2005

14. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Author

Bhatt, Deepak and Topol, Eric J.

Subjects
Therapeutics -- Comparative analysis, Aspirin -- Health aspects, Aspirin -- Comparative analysis, Coronary heart disease -- Drug therapy, Homeopathy -- Materia medica and therapeutics, Homeopathy -- Comparative analysis, Health, Plavix (Medication) -- Comparative analysis, Plavix (Medication) -- Health aspects
Published
2004

17. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes

Author

McGuire, Darren K., Newby, L. Kristin, Bhapkar, Manjushri V., Moliterno, David J., Hochman, Judith S., Klein, Werner W., Weaver, W. Douglas, Pfisterer, Matthias, Corbalan, Ramon, Dellborg, Mikael, Granger, Chrisotpher B., Van De Werf, Frans, Topol, Eric J., and Califf, Robert M.

Subjects
Diabetics -- Health aspects, Diabetics -- Research, Coronary heart disease -- Patient outcomes, Coronary heart disease -- Risk factors, Diabetes -- Complications and side effects, Diabetes -- Patient outcomes, Health
Published
2004

21. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial

Author

Al-Khatib, Sana M., Stebbins, Amanda L., Califf, Robert M., Lee, Kerry L., Granger, Christopher B., White, Harvey D., Armstrong, Paul W., Topol, Eric J., and Ohman, E.Magnus

Subjects
Heart attack -- Physiological aspects, Heart attack -- Case studies, Ventricular fibrillation -- Physiological aspects, Ventricular fibrillation -- Case studies, Arrhythmia -- Diagnosis, Arrhythmia -- Care and treatment, Arrhythmia -- Case studies, Health
Published
2003

22. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials

Author

Hasdai, David, Topol, Eric J., Kilaru, Rakhi, Battler, Alexander, Harrington, Robert A., Vahanian, Alec, Ohman, E. Magnus, Granger, Christopher B., Werf, Frans Van de, Simoons, Maarten L., O'Connor, Christopher M., and Holmes, David R., Jr.

Subjects
Outcome and process assessment (Health Care) -- Influence, Heart failure -- Influence, Heart failure -- Patient outcomes, Heart failure -- Research, Heart attack -- Patient outcomes, Heart attack -- Research, Health
Published
2003

23. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)

Author

Mukherjee, Debabrata, Mahaffey, Kenneth W., Moliterno, David J., Harrington, Robert A., Yadav, Jay S., Pieper, Karen S., Gallup, Dianne, Dyke, Christopher, Roe, Matthew T., Berdan, Lisa, Lauer, Michael S., Manttari, Matti, White, Harvey D., Califf, Robert M., and Topol, Eric J.

Subjects
Heart attack -- Drug therapy, Unstable angina -- Drug therapy, Anticoagulants (Medicine) -- Evaluation, Health
Published
2002

26. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)

Author

Lincoff, A. Michael, Kleiman, Neal S., Kottke-Marchant, Kandace, Maierson, Elizabeth S., Maresh, Kelly, Wolski, Katherine E., and Topol, Eric J.

Subjects
The Medicines Co. -- Product information, Thrombosis -- Prevention, Abciximab -- Health aspects, Pharmaceutical industry -- Product information, Health, Angiomax (Medication) -- Evaluation
Published
2002

27. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implications for ad hoc use of glycoprotein IIb-IIIa antagonists

Author

Mazur, Wojciech, Kaluza, Grzegorz L., Sapp, Shelly, Balog, Craig, Topol, Eric J., Mark, Daniel B., Ellis, Stephen G., Kereiakes, Dean J., Lincoff, A. Michael, and Kleiman, Neal S.

Subjects
Abciximab -- Evaluation, Stent (Surgery) -- Health aspects, Coronary heart disease -- Drug therapy, Health
Published
2002

30. Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO angiographic experience

Author

Lundergan, Conor F., Ross, Allan M., McCarthy, William F., Reiner, Jonathan S., Boyle, Deneane, Fink, Cynthia, Califf, Robert M., Topol, Eric J., Simoons, Maarten L., Brand, Marcel van den, Werf, Frans van de, and Coyne, Karin S.

Subjects
Myocardial revascularization -- Physiological aspects, Heart attack -- Physiological aspects, Health
Published
2001

34. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial

Author

Cohen, Mauricio G., Pacchiana, Cynthia M., Corbalan, Ramon, Perez, Jesus E. Isea, Ponte, Carlos I., Oropeza, Elsa Silva, Diaz, Rafael, Paolasso, Ernesto, Izasa, Daniel, Rodas, Marco A., Urrutia, Carlos E., Harrington, Robert A., Topol, Eric J., and Califf, Robert M.

Subjects
Heart attack -- Care and treatment, Discrimination in medical care -- Latin America, Health
Published
2001

38. Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate

Author

Sgarbossa, Elena B., Meyer, Peter M., Pinski, Sergio L., Pavlovic-Surjancev, Biljana, Barbagelata, Alejandro, Goodman, Shaun G., Lum, Andrea S., Underwood, Donald A., Gates, Kathy B., Califf, Robert M., Topol, Eric J., and Wagner, Galen S.

Subjects
Heart attack -- Prognosis, Cardiac patients -- Patient outcomes, Diastole (Cardiac cycle) -- Physiological aspects, Heart -- Electric properties, Health
Published
2000

40. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade

Author

Keriakes, Dean J, Berkowitz, Scott D, Lincoff, A Michael, Tcheng, James E, Wolski, Kathy, Achenbach, Rob, Melsheimer, Richard, Anderson, Keaven, Califf, Robert M, and Topol, Eric J

Subjects
Transluminal angioplasty -- Physiological aspects, Thrombocytopenia -- Risk factors, Heparin -- Dosage and administration, Health, abciximab (Medication) -- Physiological aspects
Published
2000

44. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial

Author

Topol, Eric J, Easton, J Donald, Amarenco, Pierre, Califf, Robert, Harrington, Robert, Graffagnino, Carmen, Davis, Stephen, Diener, H C, Ferguson, Janes, Fitzgerald, Desmond, Shuaib, Ashfaq, Koudstaal, Peter J, Theroux, Pierre, Van de Werf, Frans, Willerson, James T, Chan, Robert, Samuels, Robert, Ilson, Bernard, and Granett, Jeffrey

Subjects
Ischemia -- Prevention, Glycoproteins -- Physiological aspects, Arterial occlusions -- Prevention, Health
Published
2000

47. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide

Author

Hasdai, David, Holmes, David R., Jr., Criger, Douglas A., Topol, Eric J., Califf, Robert M., Wilcox, Robert G., Paolasso, Ernesto, Simoons, Maarten, Deckers, Jaap, and Harrington, Robert A.

Subjects
Heart attack -- Prognosis, Smokers -- Health aspects, Anticoagulants (Medicine) -- Health aspects, Health
Published
2000

Catalog

Books, media, physical & digital resources
See catalog results